Merck Points To Keytruda, Zepatier Promise Coming Off Lackluster Quarter
This article was originally published in The Pink Sheet Daily
Top-seller Januvia had an off quarter, as Merck predicted previously, but the pharma pointed to substantial growth for its PD-1 inhibitor and its expectations of winning HCV market share with Zepatier.
You may also be interested in...
First adjuvant and combination approvals for immuno-oncology could help revive Yervoy in melanoma; Amgen’s oncolytic cancer vaccine emerges as new mechanism for select patients, with room to grow.
“With so little publicly available information on the safety of CBD we anticipate that directly relevant studies will be needed,” explains the UK Food Standards Agency, in response to confusion within the country's CBD industry.
The UK regulator wants to be a “catalyst for change” in reducing regulatory burdens, saying that better regulation based on science is in everyone’s interest.